We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+14.45%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$128M
AUM Growth
+$10.1M
Cap. Flow
+$3.44M
Cap. Flow %
2.69%
Top 10 Hldgs %
70.42%
Holding
59
New
8
Increased
11
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$1.1M
2
PHR icon
Phreesia
PHR
+$552K
3
STOK icon
Stoke Therapeutics
STOK
+$534K
4
TXG icon
10x Genomics
TXG
+$392K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$315K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$735K
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$471K
3
BLUE
bluebird bio
BLUE
+$408K
4
TSVT
2seventy bio
TSVT
+$123K
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$91.6K

Sector Composition

Rank Sector Weight
1 Healthcare 95.37%
2 Energy 4.62%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
26
Travere Therapeutics
TVTX
$5.16B
$1.1M 0.86%
122,000
+40,000
+49% +$291K
APLS
27
DELISTED
Apellis Pharmaceuticals
APLS
$1.08M 0.84%
18,000
– –
AXDX
28
DELISTED
Accelerate Diagnostics
AXDX
$883K 0.69%
225,239
– –
PXD
29
DELISTED
Pioneer Natural Resource Co.
PXD
$855K 0.67%
3,800
– –
DCGO icon
30
DocGo
DCGO
$66.2M
$839K 0.66%
150,000
+20,000
+15% +$115K
PGNY icon
31
Progyny
PGNY
$2.49B
$818K 0.64%
22,000
+4,000
+22% +$134K
ARVN icon
32
Arvinas
ARVN
$517M
$617K 0.48%
15,000
– –
KNSA icon
33
Kiniksa Pharmaceuticals
KNSA
$4.81B
$526K 0.41%
30,000
– –
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
$490K 0.38%
40,000
– –
XENE icon
35
Xenon Pharmaceuticals
XENE
$6.38B
$461K 0.36%
10,000
– –
BLUE
36
DELISTED
bluebird bio
BLUE
$443K 0.35%
16,060
-6,700
-29% -$408K
KPTI icon
37
Karyopharm Therapeutics
KPTI
$169M
$406K 0.32%
31,322
-6,800
-18% -$91.6K
FOLD
38
DELISTED
Amicus Therapeutics
FOLD
$397K 0.31%
28,000
– –
HALO icon
39
Halozyme
HALO
$9.14B
$370K 0.29%
10,000
– –
CHRS icon
40
Coherus Oncology
CHRS
$219M
$366K 0.29%
+110,000
New +$295K
SWTX
41
DELISTED
SpringWorks Therapeutics
SWTX
$365K 0.29%
+10,000
New +$261K
BHVN
42
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$315K 0.25%
+7,365
New +$315K
KROS icon
43
Keros Therapeutics
KROS
$210M
$278K 0.22%
7,000
– –
XNCR icon
44
Xencor
XNCR
$1.39B
$261K 0.2%
12,300
– –
CGEM icon
45
Cullinan Oncology
CGEM
$1.08B
$256K 0.2%
25,114
– –
GTHX
46
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$244K 0.19%
80,000
-40,000
-33% -$75.2K
ZNTL icon
47
Zentalis Pharmaceuticals
ZNTL
$357M
$242K 0.19%
+16,000
New +$233K
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.78B
$241K 0.19%
2,500
– –
LQDA icon
49
Liquidia Corp
LQDA
$6.85B
$241K 0.19%
+20,000
New +$144K
CABA icon
50
Cabaletta Bio
CABA
$448M
$227K 0.18%
+10,000
New +$168K
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Birchview Capital held 59 positions worth $128M, up 8.6% from $118M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital's Q4 2023 filing shows 8 new, 11 increased, 8 reduced and 1 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 7,365 shares worth $315K. The largest sale was Bristol-Myers Squibb, an estimated $735K.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q4 2023 buy was Biohaven Pharmaceutical Holding Company Ltd.: 7,365 shares worth $315K.
  • Birchview Capital added most to Silk Road Medical, Inc. Common Stock in Q4 2023, an estimated $1.1M increase.
  • Birchview Capital's biggest Q4 2023 reduction was Bristol-Myers Squibb, cutting an estimated $735K.
  • Birchview Capital fully exited Nektar Therapeutics in Q4 2023, selling an estimated $16.7K.
  • Birchview Capital's ten largest holdings make up 70% of its $128M portfolio in Q4 2023.
  • Birchview Capital opened 8 new positions and closed 1 in Q4 2023.
  • Birchview Capital's portfolio value rose 8.6% quarter-over-quarter to $128M.

Based on Birchview Capital's 13F filing for Q4 2023, filed 14 Feb 2024.